Universe Pharmaceuticals CFO files initial Form 3

Universe Pharmaceuticals INC director and Chief Financial Officer Yang Lin (Lydia) filed an initial Form 3 reporting insider status in the company.

Accepted by SEC EDGAR 03/18/2026 - 08:22 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Universe Pharmaceuticals INC director and Chief Financial Officer Yang Lin (Lydia) filed an initial Form 3 reporting insider status in the company. The filing lists no purchases, sales, gifts, or other equity transactions, and shows no derivative positions in this excerpt.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Universe Pharmaceuticals (UPC) Form 3 for Yang Lin (Lydia) show?

The Form 3 shows Yang Lin (Lydia) as a director and Chief Financial Officer of Universe Pharmaceuticals. In this excerpt, it reports no stock purchases, sales, or other equity transactions and no derivative positions, serving as an initial insider ownership disclosure.

Does the UPC Form 3 for Yang Lin (Lydia) report any stock transactions?

No transactions are reported for Yang Lin (Lydia) in this Form 3 excerpt. The transaction summary shows zero buys, zero sells, zero gifts, and zero derivative exercises, indicating only an initial insider status filing without trading activity disclosed here.

What roles does Yang Lin (Lydia) hold at Universe Pharmaceuticals (UPC)?

Yang Lin (Lydia) is identified as both a director and an officer of Universe Pharmaceuticals, serving as Chief Financial Officer. The Form 3 records these roles as part of the insider profile while showing no reported share transactions in the provided data.

Are any derivative securities reported for Yang Lin (Lydia) at UPC?

No derivative securities are listed for Yang Lin (Lydia) in this Form 3 excerpt. The derivative summary is empty and derivativeTransactionCount is zero, indicating no options, warrants, or similar instruments are reported in the visible portion of the filing.

Does the UPC Form 3 show Yang Lin (Lydia) as a 10% owner?

The Form 3 indicates Yang Lin (Lydia) is not a ten percent owner of Universe Pharmaceuticals. She is reported instead as a director and officer, specifically the Chief Financial Officer, with no share transactions disclosed in this data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Yang Lin (Lydia)

(Last) (First) (Middle)

265 JINGJIU AVENUE

JINGGANGSHAN ECON. AND TECH. DEV. ZONE

(Street)

JI'AN, JIANGXI 343100

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Universe Pharmaceuticals INC [ UPC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	_/s/ Lin Yang	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)